Micafungin use in children

References

• Steinbach WJ. Epidemiology of invasive fungal infections in neonates and children. Clin. Microbiol. Infect.16, 1321–1327 (2010).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev.20, 133–163 (2007).
   PubMed Web of Science ®Google Scholar
• Zaoutis T. Candidemia in children. Curr. Med. Res. Opin.26, 1761–1768 (2010).
   PubMed Web of Science ®Google Scholar
• Dornbusch HJ, Manzoni P, Roilides E et al. Invasive fungal infections in children. Pediatr. Infect. Dis. J.28, 734–737 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufman DA. Challenging issues in neonatal candidiasis. Curr. Med. Res. Opin.26, 1769–1778 (2010).
   PubMed Web of Science ®Google Scholar
• Blyth CC, Chen SCA, Slavin MA et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics123, 1360–1368 (2009).
   PubMed Web of Science ®Google Scholar
• Burgos A, Zaoutis TE, Dvorak CC et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics121, e1286–e1294 (2008).
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin. Infect. Dis.42, 1171–1178 (2006).
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat.10, 121–130 (2007).
   PubMed Web of Science ®Google Scholar
• Walker LA, Gow NA, Munro CA. Fungal echinocandin resistance. Fungal. Genet. Biol.47, 117–126 (2010).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol.20, 121–136 (2003).
   PubMedGoogle Scholar
• Pound MW, Townsend ML, Drew RH. Echinocandin pharmacodynamics: review and clinical implications. J. Antimicrob. Chemother.65, 1108–1118 (2010).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts (3rd Edition). Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
   Google Scholar
• Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Informational supplement M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
   Google Scholar
• Messer SA, Diekema DJ, Boyken L et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol.44, 324–326 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol.48, 52–56 (2010).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int. J. Infect. Dis.14, e954–e966 (2010).
   PubMed Web of Science ®Google Scholar
• Kuhn DM, George T, Chandra J et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother.46, 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Gil-Lamaignere C, Salvenmoser S, Hess R et al. Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae. Antimicrob. Agents Chemother.48, 2730–2732 (2004).
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard (2nd Edition). M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2008).
   Google Scholar
• Arikan S, Yurdakul P, Hascelik G. Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp. Antimicrob. Agents Chemother.47, 2640–2643 (2003).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ et al.In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method. J. Clin. Microbiol.47, 3323–3325 (2009).
   PubMed Web of Science ®Google Scholar
• Ikeda F, Saika T, Sato Y et al. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan. Med. Mycol.47, 145–148 (2009).
   PubMed Web of Science ®Google Scholar
• Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)β-glucan synthase activity is sensitive to echinocandins. Antimicrob. Agents Chemother.49, 2851–2856 (2005).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nakase K, Ino K et al. Breakthrough cryptococcosis in a patient with systemic lupus erythematosus (SLE) receiving micafungin. J. Infect. Chemother.14, 311–314 (2008).
   PubMedGoogle Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.15, 1407–1416 (2004).
   Google Scholar
• Matsue K, Uryu H, Koseki M, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis.42, 753–757 (2006).
   PubMed Web of Science ®Google Scholar
• Akagi T, Yamaguti K, Kawamura T et al. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk. Lymphoma47, 1182–1183 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki K, Sugawara Y, Sekine T et al. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. J. Infect. Chemother.15, 42–45 (2009).
   PubMed Web of Science ®Google Scholar
• Heresi GP, Gerstmann DR, Reed MD et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr. Infect. Dis. J.25, 1110–1115 (2006).
   PubMed Web of Science ®Google Scholar
• Prasad PA, Coffin SE, Leckerman KH et al. Pediatric antifungal utilization: new drugs, new trends. Pediatr. Infect. Dis. J.27, 1083–1088 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta PA, Vinks AA, Filipovich A et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol. Blood Marrow Transplant.16, 1458–1462 (2010).
   PubMed Web of Science ®Google Scholar
• Mycamine package insert. Astellas Pharma, USA.
   Google Scholar
• Funguard package insert. Astellas Pharma, Japan.
   Google Scholar
• Hebert MF, Smith HE, Marbury TC et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol.45, 1145–1152 (2005).
   PubMed Web of Science ®Google Scholar
• Groll AH, Mickiene D, Petraitis V et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother.45, 3322–3327 (2001).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med. Mycol.47, S369–S375 (2009).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species related differences. Antimicrob. Agents Chemother.51, 2257–2259 (2007).
   PubMed Web of Science ®Google Scholar
• Fleischhacker M, Radecke C, Schulz B et al. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur. J. Clin. Microbiol. Infect. Dis.27, 127–131 (2008).
   PubMed Web of Science ®Google Scholar
• Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with pesistent neutropenia. Antimicrob. Agents Chemother.51, 968–974 (2007).
   PubMed Web of Science ®Google Scholar
• Lewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. J. Antimicrob. Chemother.61, 1140–1144 (2008).
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T et al. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother.52, 321–328 (2008).
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Cota JM, Frei CR. Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infect. Drug Resist.1, 63–77 (2008).
   PubMedGoogle Scholar
• Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob. Agents Chemother.49, 3317–3324 (2005).
   PubMed Web of Science ®Google Scholar
• Tabata K, Katashima M, Kawamura A et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol. Pharm. Bull.29, 1706–1711 (2006).
   PubMed Web of Science ®Google Scholar
• Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother.51, 3714–3719 (2007).
   PubMed Web of Science ®Google Scholar
• Smith PB, Walsh TJ, Hope WW et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr. Infect. Dis. J.28, 412–415 (2009).
   PubMed Web of Science ®Google Scholar
• Hope WW, Smith PB, Arrieta A et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob. Agents Chemother.54, 2633–2637 (2010).
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Smith PB, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin. Pharmacol. Ther.87, 93–99 (2010).
   PubMed Web of Science ®Google Scholar
• Kawada M, Fukuoka N, Kondo M et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr. Infect. Dis. J.28, 840–842 (2009).
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob. Agents Chemother.49, 1331–1336 (2005).
   PubMed Web of Science ®Google Scholar
• Hope WW, Mickiene D, Petraitis V et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J. Infect. Dis.1, 163–171 (2008).
   Google Scholar
• Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis.24, 654–661 (2005).
   PubMed Web of Science ®Google Scholar
• Queiroz-Telles F, Berezin E, Leverger G et al. Micafungin invasive candidiasis study group. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr. Infect. Dis. J.27, 820–826 (2008).
   PubMed Web of Science ®Google Scholar
• Kawaguchi C, Arai I, Yasuhara H et al. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr. Int.51, 220–224 (2009).
   PubMed Web of Science ®Google Scholar
• Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J. Perinatol.29, 738–743 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46, 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect.53, 337–349 (2006).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Ratanatharathorn V, Young JA et al. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transpl. Infect. Dis.11, 89–93 (2009).
   PubMed Web of Science ®Google Scholar
• Flynn P, Seibel N, Arrieta AC et al. Treatment of invasive aspergillosis in pediatric patients with micafungin alone or in combination with other systemic antifungal agents. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 (2006) (Abstract M-891).
   Google Scholar
• Ikawa K, Nomura K, Morikawa N et al. Assessment of micafungin regimens by pharmacokinetic–pharmacodynamic analysis: a dosing strategy for Aspergillus infections. J. Antimicrob. Chemother.64, 840–844 (2009).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Murayama S, Tatsuzawa O et al. X-linked severe combined immunodeficiency (X-SCID) with high blood levels of immunoglobulins and Aspergillus pneumonia successfully treated with micafangin followed by unrelated cord blood stem cell transplantation. Eur. J. Pediatr.166, 207–210 (2007).
   PubMed Web of Science ®Google Scholar
• Santos RP, Sánchez PJ, Mejias A et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr. Infect. Dis. J.26, 364–366 (2007).
   PubMed Web of Science ®Google Scholar
• Kusuki S, Hashii Y, Yoshida H et al. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr. Blood Cancer.53, 605–609 (2009).
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis.46, 1813–1821 (2008).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maddison P, Ullmann AJ. Pooled analysis of safety for micafungin. Crit. Care12(Suppl. 2), P21 (2008).
   Google Scholar